Drs Steven Finkelstein and Louis J. Mazzarelli comment on limitations associated with conventional imaging modalities in prostate cancer and highlight the roles of newer tests such as 18F-fluciclovine and 68Ga-PSMA-11.
18F-Fluciclovine Versus 68Ga-PSMA-11 Imaging for Prostate Cancer Biochemical Recurrence
EP. 2: Presentation: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer
Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.
Reactions to key findings from an article by Birgit Pernthaler, et al, that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer.
Interesting questions raised by a paper that compared the use of 18F-fluciclovine with 68Ga-PSMA-11 imaging modalities to detect biochemical relapse in prostate cancer and implications for integrating newer techniques into clinical practice.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
What a Large Prostate MRI Study Reveals About AI and Unassisted Radiologist Assessment
2
FDA Clears First MRI-Derived AI Software for Assessing Breast Cancer Recurrence Risk
3
How Photon-Counting CT Helps Us Recognize that Coronary Stenosis is Just One Piece of the Puzzle
4
Breast Imaging in Focus: Can AI Models for Breast Cancer Detection and Risk Prediction Be Used Interchangeably?
5